Results were announced from a phase 3 trial evaluating solriamfetol for major depressive disorder with/without severe excessive daytime sleepiness.

Topline results were announced from a phase 3 trial evaluating solriamfetol for the treatment of major depressive disorder (MDD) with and without severe excessive daytime sleepiness (EDS).

Compared with placebo, pitolisant 20 and 40 mg had a greater treatment response for residual excessive daytime sleepiness ... and an Epworth Sleepiness Scale (ESS) score of 14.9, 14.2, and 14.0 ...

Carosella, MD Among patients with obstructive sleep apnea and excessive daytime sleepiness-related cognitive ... placebo (19%; n = 11 vs. 10%; n = 6). The study noted that reported adverse events ...

Alkermes plc (Nasdaq: ALKS) today announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to placebo in adults with idiopathic ...

with and without severe excessive daytime sleepiness (EDS). In the overall patient population, the study did not demonstrate a statistically significant change on the Montgomery-Åsberg Depression ...

Investigating Sunosi as a treatment for MDD patients with and without excessive daytime sleepiness (EDS), a phase 3, proof-of-concept study did not meet its primary endpoint, Axsome said Tuesday.

Participants will be randomized to receive one of three doses of ALKS 2680 (10 mg, 14 mg or 18 mg ... the orexin system may address excessive daytime sleepiness across hypersomnolence disorders ...

The National Weather Service in Memphis warned of "catastrophic flooding" of at least 10 inches of rain for areas north of I-40 by this weekend. LOOKING AHEAD: Isolated storms Friday (40% ...

MEMPHIS, Tenn. - A rare and dangerous High Risk (5/5) for severe weather has been issued for parts of the Mid-South. This is the highest risk level issued by the Storm Prediction Center and ...